Results 61 to 70 of about 260,030 (390)

An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. [PDF]

, 2009
To address the biological heterogeneity of lung cancer, we studied 199 lung adenocarcinomas by integrating genome-wide data on copy number alterations and gene expression with full annotation for major known somatic mutations in this cancer.
Brennan, C, Broderick, S, Chitale, D, Gerald, W, Golas, B, Gong, Y, Ladanyi, M, Major, J, Motoi, N, Pao, W, Reinersman, J, Rusch, V, Sander, C, Seshan, V, Somwar, R, Szoke, J, Taylor, Barry, Wang, L, Zakowski, M   +18 more
core   +5 more sources

KRAS‐G12D mutation drives immune suppression and the primary resistance of anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer

Cancer Communications, 2022
Although immune checkpoint inhibitors (ICIs) against programmed cell death protein 1 (PD‐1) and its ligand PD‐L1 have demonstrated potency towards treating patients with non‐small cell lung carcinoma (NSCLC), the potential association between Kirsten rat
Chengming Liu, Sufei Zheng, Zhanyu Wang, Sihui Wang, Xinfeng Wang, Lu Yang, Haiyan Xu, Z. Cao, Xiaoli Feng, Q. Xue, Yan Wang, N. Sun, Jie He   +12 more
semanticscholar   +1 more source

Characterizing genomic alterations in cancer by complementary functional associations. [PDF]

, 2016
Systematic efforts to sequence the cancer genome have identified large numbers of mutations and copy number alterations in human cancers. However, elucidating the functional consequences of these variants, and their interactions to drive or maintain ...
A Azzalini, A Kraskov, A Kraskov, A Singh, A Young, AA Margolin, AJ Butte, Amir Reza Alizad-Rahvar, Andrew Aguirre, Arthur Liberzon, Aviad Tsherniak, B Luo, Barbara A Weir, C Ding, C Scholl, CA Miller, CD Correa, Chet Birger, Chiara Romualdi, CJ Vaske, Cory M Johannessen, D Feng, D Guardavaccaro, D Malhotra, D Nijhawan, D Pandey, DA Barbie, Daniel DiCara, David A Barbie, David J Konieczkowski, DD Shao, Diane D Shao, DP Hollern, DP Minde, DV Foster, EH Linfoot, Eliezer M Van Allen, F Vandin, F Vandin, Francisca Vazquez, G Ciriello, GA Darbellay, Gabriela Alexe, Gabriele Sales, Gad Getz, GM DeNicola, H Joe, H Peng, H Zou, Heidi Greulich, HW Cheung, J Barretina, J Lin, J Rosenbluh, JA McCubrey, Jesse S Boehm, Jill P Mesirov, JN Weinstein, Jong Wook Kim, Joseph Rosenbluh, JP Brunet, JS Boehm, L Chin, L Chin, L Waldron, Levi A Garraway, LM Solis, M Meyerson, Mahmoud Ghandi, Masoud Ardakani, MB Raeder, MD Leiserson, ME Abazeed, Michael Noble, Mohamed E Abazeed, MS Lawrence, MS Lawrence, Olga B Botvinnik, Omar Abudayyeh, P Tamayo, Pablo Tamayo, Peter S Hammerman, R Beroukhim, R Firestein, R Steuer, Rameen Beroukhim, S Pendyala, S Sheather, SS Brar, T Valenta, Travis I Zack, William C Hahn, Y Gu, Yashaswi Shrestha   +93 more
core   +1 more source

NOSILNA ZMOGLJIVOST OBČIN TOLMIN, KOBARID IN KOMEN ZA TURIZEM

Acta Geographica Slovenica, 2022
Pri raziskovanju nosilne zmogljivosti za turizem v občinah Tolmin, Kobarid in Komen smo ugotovili, da sta najbolj problematični infrastrukturna in ekonomska nosilna zmogljivost, pri katerih je večina dejavnikov presežena v času poletne sezone.
Igor Jurinčič
doaj   +1 more source

Drugging KRAS: current perspectives and state-of-art review

Journal of Hematology & Oncology, 2022
After decades of efforts, we have recently made progress into targeting KRAS mutations in several malignancies. Known as the ‘holy grail’ of targeted cancer therapies, KRAS is the most frequently mutated oncogene in human malignancies.
K. Parikh, G. Banna, Stephen V. Liu, A. Friedlaender, A. Desai, V. Subbiah, A. Addeo   +6 more
semanticscholar   +1 more source

EGFR inhibitor as second-line therapy in a patient with mutant RAS metastatic colorectal cancer: circulating tumor DNA to personalize treatment [PDF]

, 2018
A 47-year-old male patient presented in March 2016 to our unit with a palpable painless left supraclavicular mass. A whole-body contrastenhanced computed tomography (CT) scan revealed a left supraclavicular lymphadenopathy, transverse colon thickening ...
Cortesi, Enrico, Gazzaniga, Paola, Raimondi, Cristina, Urbano, Federica   +3 more
core   +1 more source

Neolitske risbe v jami Bestažovci na Krasu

Arheološki Vestnik, 2022
Jama Bestažovca je del starega vodoravnega jamskega rova, ki so ga preoblikovali zapolnitve s sedimenti, kraška denudacija in podiranja. Glavni rov Bestažovce je bil do nedavnega povezan s Perkovo pečino, o čemer pričajo arheološki ostanki ...
Andrej Mihevc
doaj   +1 more source

Elevated FSP1 protects KRAS-mutated cells from ferroptosis during tumor initiation

Cell Death and Differentiation, 2022
Oncogenic KRAS is the key driver oncogene for several of the most aggressive human cancers. One key feature of oncogenic KRAS expression is an early increase in cellular reactive oxygen species (ROS) which promotes cellular transformation if cells manage
F. Müller, Jonathan K. M. Lim, Christina M. Bebber, Eric Seidel, Sofya Tishina, Alina Dahlhaus, J. Stroh, Julia Beck, F. I. Yapici, K. Nakayama, Lucia A. Torres Fernández, J. Brägelmann, G. Leprivier, S. von Karstedt   +13 more
semanticscholar   +1 more source

PIK3CA mutations in advanced cancers: characteristics and outcomes. [PDF]

, 2012
PIK3CA mutations are frequently diagnosed in diverse cancers and may predict response to PI3K/AKT/mTOR inhibitors. It remains unclear whether they are associated with other characteristics.
Falchook, Gerald S, Fu, Siqing, Garrido-Laguna, Ignacio, Hong, David S, Janku, Filip, Kurzrock, Razelle, Lee, Jack J, Luthra, Rajyalakshmi, Moulder, Stacy L, Naing, Aung, Piha-Paul, Sarina A, Stepanek, Vanda M, Tsimberidou, Apostolia M, Wheler, Jennifer J   +13 more
core   +4 more sources

Biskup, papieski inkwizytor i heretycy. Uwagi o dokumentacji procesów o herezję w księdze biskupa włocławskiego Zbigniewa Oleśnickiego (1473-1481)

Roczniki Historyczne
W styczniu 1480 r., przed sądem biskupa włocławskiego Zbigniewa Oleśnickiego rozpoczęły się przesłuchania mieszkańców Inowrocławia w sprawie miejscowych sympatyków husytyzmu.
Paweł Kras
doaj   +1 more source